Agamree (vamorolone) — United Healthcare
Duchenne muscular dystrophy (DMD)
Preferred products
- prednisone
Initial criteria
- Published clinical evidence shows Agamree is likely to produce equivalent therapeutic results as other available corticosteroids (e.g., prednisone)
- Agamree is not medically necessary for treatment of Duchenne muscular dystrophy
- Agamree is typically excluded from coverage
- State mandates may apply
- Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria
- Tried/Failed criteria may be in place (refer to plan specifics to determine exclusion status)